hVIVO strengthens Board with appointment of Richard Cotton as Non-Executive Director Seasoned life sciences executive with extensive Board and financial expertise
Shore Capital Reaffirms Buy Rating on hVIVO Despite Share Price Weakness
Shore Capital has maintained its Buy rating on hVIVO PLC, the specialist contract research organisation, with a fair value assessment of 25 pence per share.
Roquefort Therapeutics shares jump 61% after an agreement to sell its subsidiary, Oncogeni.
Roquefort Therapeutics PLC (LON: ROQ) has agreed to sell its subsidiary, Oncogeni, to UAE-based Nations Trust Holding in a deal worth up to $12 million (£9.3 million).
Roquefort Therapeutics plc (LSE:ROQ,OTCQB:ROQAF) Midkine Antibody Licencing Deal
Roquefort Therapeutics plc (LSE: ROQ, OTCQB: ROQAF), the Main Market listed biotech company focused on developing first in class medicines in the high value and high growth immuno-oncology market is pleased to announce
Zak Mir talks to Adrian Kinkaid, CEO (AIM:FAB) Fusion Antibodies
Fusion Antibodies plc (AIM: FAB), as the Early Discovery Contract Research Organisation specialising in pre-clinical antibody discovery, announces its unaudited interim results for the six months ended 30 September 2023
Redx Pharma is advancing with ts primary asset, RXC007
Redx Pharma PLC (AIM: REDX) announced that its primary asset, RXC007, is successfully moving through phase IIa testing, with anticipated results from the idiopathic pulmonary fibrosis research due in the
Why UK small-cap biotech shares are going extinct, AVCT, RENE, POLX, HVO & HEMO
When a UK biotech firm starts to show promise, they set sail across the Atlantic. Investors can’t blame them.
The Essential Investing Strategy Review For 2023, HARL, PREM, AVCT, & BOIL
Buying lottery tickets on the FTSE AIM can be very rewarding, but only for investors who have already properly diversified.
Diversification: the essential investing strategy for 2023
Buying lottery tickets on the FTSE AIM can be very rewarding, but only for investors who have already properly diversified.
Redx Pharma plc (AIM:REDX) Collaboration with the Garvan Institute
Redx Announces Collaboration with the Garvan Institute of Medical Research
Women are pushing forward groundbreaking Alzheimer’s treatment ideas that go beyond the headlines
The medical community is now closer than ever to finding treatments for Alzheimer’s disease.
The highs and lows of drug launches
Every drug has its beneficiaries, whether they are suffering from a common chronic disease, a more severe form of cancer or a rare condition that affects 1 in 10,000 people. However,